Brunetti Luigi, Leone Sheila, Orlando Giustino, Recinella Lucia, Ferrante Claudio, Chiavaroli Annalisa, Di Nisio Chiara, Di Michele Pierpaolo, Vacca Michele
Department of Drug Sciences, G. d'Annunzio University, School of Pharmacy, via dei Vestini, 66013 Chieti, Italy.
Peptides. 2009 Jul;30(7):1323-7. doi: 10.1016/j.peptides.2009.04.011. Epub 2009 May 3.
Obestatin is a gastric derived 23 amino acid peptide, which has shown anorectic effects in a number of experimental paradigms after both peripheral and central administration. On the other hand, several researchers were not able to confirm these data. Since all previous experiments have been performed in animals fed a standard laboratory diet, we studied obestatin effects in male Wistar rats fed both a standard laboratory chow (STD) diet (3.5% fat, 63% carbohydrate, 14% protein, 19.5% other components without caloric value; 3.20 kcal/g) and a highly palatable cafeteria-style (CAF) diet (30% fat, 56% carbohydrate, 14% protein; 4.20 kcal/g). Vehicle or obestatin (10, 50 or 100 nmol/kg) was injected intraperitoneally daily for 12 days. In STD diet rats, obestatin decreased daily caloric intake and body weight gain compared to vehicle treated rats. The anorectic and weight reducing effects of obestatin treatment were evidenced since day 6 and day 8 of treatment, respectively, and were consistent through the end of treatment. On the other hand, in CAF diet rats, obestatin treatment did not modify either daily caloric intake or body weight gain. In CAF diet rats, the percentage intake from standard food was decreased, balanced by an increase in cafeteria food intake. Obestatin treatment affected neither water consumption nor the intake of any specific food within the cafeteria diet. In conclusion, obestatin decreases caloric intake and body weight gain, but only in rats fed a STD diet.
肥胖抑制素是一种由胃产生的含23个氨基酸的肽，在经外周和中枢给药后的多种实验范式中均显示出厌食作用。另一方面，一些研究人员无法证实这些数据。由于之前所有实验均在喂食标准实验室饮食的动物身上进行，我们研究了肥胖抑制素对喂食标准实验室普通饲料（STD）（3.5%脂肪、63%碳水化合物、14%蛋白质、19.5%无热量价值的其他成分；3.20千卡/克）和高适口性自助式（CAF）饮食（30%脂肪、56%碳水化合物、14%蛋白质；4.20千卡/克）的雄性Wistar大鼠的影响。每天腹腔注射溶媒或肥胖抑制素（10、50或100纳摩尔/千克），持续12天。在STD饮食的大鼠中，与接受溶媒治疗的大鼠相比，肥胖抑制素降低了每日热量摄入和体重增加。肥胖抑制素治疗的厌食和减重作用分别在治疗的第6天和第8天得到证实，并在治疗结束时保持一致。另一方面，在CAF饮食的大鼠中，肥胖抑制素治疗既未改变每日热量摄入，也未改变体重增加。在CAF饮食的大鼠中，标准食物的摄入量百分比降低，同时自助餐厅食物摄入量增加，二者相平衡。肥胖抑制素治疗既不影响水的消耗，也不影响自助餐厅饮食中任何特定食物的摄入量。总之，肥胖抑制素可降低热量摄入和体重增加，但仅在喂食STD饮食的大鼠中如此。
